MRNA Stock Price Today (September 2026) — Moderna, Inc. Analysis & Key Metrics 2026-09-03
Moderna, Inc. (MRNA) is trading at $148.87, down 1.29% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $106.63 (-28.4% upside).
- Volatility remains elevated (385.11% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.10% YoY) alongside significant competitive pressures.
MRNA Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Moderna, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $51.24B
P/E Ratio
Forward P/E: -30.70
Revenue Growth
Year over Year
Analyst Target
+-28.4% upside potential
Key Investor Questions About MRNA
What investors need to know before buying
Based on current market data, MRNA presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 64.79)
- Fundamentals say: Caution warranted (high leverage concerns)
MRNA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRNA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.29B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, MRNA stock traded between $22.28 and $176.66—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 385.11% annualized volatility and β=1.54, the stock exhibits high sensitivity to market moves—making MRNA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Moderna (MRNA) Stock Is Down Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target to $81 from $40, representing a 46% downside from the previous day’s close of $150.81, CNBC reported.
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Both have attracted considerable attention from Wall Street recently.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Bamco, the advisory arm of Ron Baron’s Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna shares nearly tripled on a positive Phase 3 report. Bamco also […]
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Jim Cramer Explains Why Heavily Shorted Moderna (MRNA) Has Room to Run
During the August 31 episode of Mad Money, Jim Cramer addressed shifting market dynamics, highlighting how the fallout from heavily crowded hedge fund positions was finally unwinding. Turning his attention to a heavily shorted stock on Wall Street, Cramer pointed to Moderna, Inc. (NASDAQ:MRNA) and explained why skeptics were forced to rethink their thesis. He […]
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]
Explore More Analysis for MRNA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Moderna, Inc.
Moderna, Inc. (MRNA) is currently trading at $148.87. The RSI (14-day) is at 64.8, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $106.63 implies 28.4% downside from current levels. Volatility is high at 385.1% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Moderna, Inc. (MRNA): The trailing P/E ratio is -18.66, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -30.70, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 8.79. Price-to-Sales is 26.68. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 16 analysts covering MRNA, the consensus price target is $106.63. This represents a 28.4% downside from the current price of $148.87. The range spans from a low target of $40.00 to a high target of $170.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Moderna, Inc. (MRNA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Moderna, Inc. (MRNA) investors include: 1. High volatility (385.1% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (16.2% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Moderna, Inc.'s (MRNA) current debt and financial health profile: Total debt stands at $1.29B. The debt-to-equity ratio is 19.04, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 2.29, indicating strong short-term liquidity. The quick ratio is 2.07. The company holds $5.14B in cash and equivalents. Free cash flow is positive at $299.25M, providing a cushion for debt servicing and shareholder returns.